GABA-A receptor comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-09-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
| Property | Value | Notes |
|---|---|---|
| Peptide sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Seven residues; tuftsin plus a Pro-Gly-Pro tail |
| Molecular formula | C33H57N11O9 | Commonly reported value for the free peptide |
| Monoisotopic mass | Roughly 751.4 Da | Average molecular mass near 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Freely soluble in water | Also dissolves in saline and other polar solvents |
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
== Limits and extensions of PBPK modeling == Each type of modeling technique has its strengths and limitations. PBPK modeling is no exception. One limitation is the potential for a large number of parameters, some of which may be correlated. This can lead to the issues of parameter identifiability and redundancy. However, it is possible (and commonly done) to model explicitly the correlations between parameters (for example, the non-linear relationships between age, body-mass, organ volumes and blood flows). After numerical values are assigned to each PBPK model parameter, specialized or general computer software is typically used to numerically integrate a set of ordinary differential equations like those described above, in order to calculate the numerical value of each compartment at specified values of time (see Software). However, if such equations involve only linear functions of each compartmental value, or under limiting conditions (e.g., when input values remain very small) that guarantee such linearity is closely approximated, such equations may be solved analytically to yield explicit equations (or, under those limiting conditions, very accurate approximations) for the time-weighted average (TWA) value of each compartment as a function of the TWA value of each specified input (see, e.g.,). PBPK models can rely on chemical property prediction models (QSAR models or predictive chemistry models) on one hand. For example, QSAR models can be used to estimate partition coefficients.
=== The Buck Institute for Research on Aging === In November 2016, Verdin became president and CEO of the Buck Institute for Research on Aging. The Buck Institute is the first independent research center focused solely on aging. As of 2022, it had an operating budget of $65 million a year and around 300 employees. The Buck's first human clinical trial, Buck Institute Ketone Ester (BIKE), was announced in 2023. In 2025, Verdin was named a scientific ambassador for Alliance for Longevity Science, Arts & Entertainment (ALSAE), a partner organization of the Buck Institute.
==== Early synthesis by the Buddha ==== According to Erich Frauwallner, the twelvefold chain resulted from the Buddha's combination of two lists. Originally, the Buddha explained the appearance of dukkha from tanha, "thirst", craving. Later on, the Buddha incorporated avijja, "ignorance", as a cause of suffering into his system. This is described in the first part of dependent origination. Frauwallner saw this "purely mechanical mixing" as "enigmatical", "contradictory" and a "deficiency in systematization". Paul Williams discusses Frauwallner's idea that the 12 links may be a composite. However, he ultimately concludes that "it may be impossible at our present stage of scholarship to work out very satisfactorily what the original logic of the full twelvefold formula was intended to be, if there ever was one intention at all."
== Philanthropy == The Foundation has made significant donations to buildings and other works at Downing College Cambridge University. In particular, the Howard Building (1986) and the Howard Lodge (1991) both designed by Quinlan Terry and the Howard Theatre designed by Quinlan and Francis Terry (2009). The Foundation sponsored the book by Tim Rawle: A Classical Adventure – the Architectural History of Downing College, Cambridge. The Foundation also made donations to the Waterford Institute of Technology towards the construction of the Howard Laboratory (an analytical chemical laboratory) and the Howard Gate at Carriganore House, on the west campus of the Waterford Institute of Technology.
Sources: en.wikipedia.org
Mycosporine-like amino acids (MAAs) are small secondary metabolites produced by organisms that live in environments with high volumes of sunlight, usually marine environments. The exact number of compounds within this class of natural products is yet to be determined, since they have only relatively recently been discovered and novel molecular species are constantly being discovered; however, to date their number is around 30. They are commonly described as "microbial sunscreens" although their function is believed not to be limited to sun protection. MAAs represent high potential in cosmetics, and biotechnological applications. Indeed, their UV-absorbing properties would allow to create products derived from natural photoprotectors, potentially harmless to the environment and efficient against UV damage.
Despite its widespread use, there is only mixed evidence that silver in dressings has any benefit. A 2018 Cochrane review found that silver-containing dressings may increase the probability of healing for venous leg ulcers. A number of wound dressings containing silver as an anti-bacterial have been cleared by the U.S. Food and Drug Administration (FDA). However, silver-containing dressings may cause staining, and in some cases tingling sensations as well.
This reaction is relatively slow, so even after significant exposure, the 239Pu is still mixed with a great deal of 238U (and possibly other isotopes of uranium), oxygen, other components of the original material, and fission products. Only if the fuel has been exposed for a few days in the reactor, can the 239Pu be chemically separated from the rest of the material to yield high-purity 239Pu metal. 239Pu has a higher probability for fission than 235U and a larger number of neutrons produced per fission event, so it has a smaller critical mass. Pure 239Pu also has a reasonably low rate of neutron emission due to spontaneous fission (10 fission/s·kg), making it feasible to assemble a mass that is highly supercritical before a detonation chain reaction begins. In practice, however, reactor-bred plutonium will invariably contain a certain amount of 240Pu due to the tendency of 239Pu to absorb an additional neutron during production. 240Pu has a high rate of spontaneous fission events (415,000 fission/s-kg), making it an undesirable contaminant. As a result, plutonium containing a significant fraction of 240Pu is not well-suited to use in nuclear weapons; it emits neutron radiation, making handling more difficult, and its presence can lead to a "fizzle" in which a small explosion occurs, destroying the weapon but not causing fission of a significant fraction of the fuel. It is because of this limitation that plutonium-based weapons must be implosion-type, rather than gun-type.
Promising results of health and medical research are reported: further evidence that breastfeeding is important for the cognitive child development due to its unique ingredients (11 July), trialed hydroxyapatite toothpaste – which can also include fluoride in addition – against caries (18 July), gene therapy eyedrops of Vyjuvek, which was approved in May, against blindness (24 July), the second release from the global WikiGuidelines, a practically oriented guideline on the diagnosis and management of infective endocarditis, demonstrates a novel approach that incorporates uncertainties more than conventional guideline reviews (31 July).
== Applications == Surfactants are widely used due to their ability to modify surface and interfacial properties, making them relevant in processes involving the interaction of hydrophobic and hydrophilic substances. Their amphiphilic nature—containing both hydrophilic and hydrophobic parts—enables them to bridge these otherwise immiscible components, thereby facilitating mixing and enhancing the efficiency of various physical and chemical transformations. This makes surfactants useful in numerous fields where control over interfacial interactions is relevant. Surfactants play an important role as cleaning, wetting, dispersing, emulsifying, foaming and anti-foaming agents in many practical applications and products, including detergents, fabric softeners, motor oils, emulsions, soaps, paints, adhesives, inks, anti-fogs, ski waxes, snowboard wax, in flotation, washing and enzymatic processes, and laxatives.
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.
No peptide with this exact sequence has been identified as an endogenous substance. It is a laboratory-designed analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The Pro-Gly-Pro extension has no known natural source.
Proline introduces conformational constraints that make a peptide less accessible to common peptidases. This is a standard stabilization strategy in peptide design. The added residues also increase the distance between the active tuftsin portion and typical cleavage sites.
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.